A randomized controlled trial comparing mupirocin and polysporin triple ointments in peritoneal dialysis patients: the MP3 Study
- PMID: 22134627
- PMCID: PMC3280035
- DOI: 10.2215/CJN.07970811
A randomized controlled trial comparing mupirocin and polysporin triple ointments in peritoneal dialysis patients: the MP3 Study
Abstract
Background and objectives: Infectious complications remain a significant cause of peritoneal dialysis (PD) technique failure. Topical ointments seem to reduce peritonitis; however, concerns over resistance have led to a quest for alternative agents. This study examined the effectiveness of applying topical Polysporin Triple ointment (P(3)) against mupirocin in a multi-centered, double-blind, randomized controlled trial.
Design, setting, participants, & measurements: PD patients routinely applied either P(3) or mupirocin ointment to their exit site. Patients were followed for 18 months or until death or catheter removal. The primary study outcome was a composite endpoint of exit-site infection (ESI), tunnel infection, or peritonitis.
Results: Seventy-five of 201 randomized patients experienced a primary outcome event (51 peritonitis episodes, 24 ESIs). No difference was seen in the time to first event for P(3) (13.2 months; 95% confidence interval, 11.9-14.5) and mupirocin (14.0 months; 95% confidence interval, 12.7-15.4) (P=0.41). Twice as many patients reported redness at the exit site in the P(3) group (14 versus 6, P=0.10). Over the complete study period, a higher rate per year of fungal ESIs was seen in patients using P(3) (0.07 versus 0.01; P=0.02) with a corresponding increase in fungal peritonitis (0.04 versus 0.00, respectively; P<0.05).
Conclusions: This study shows that P(3) is not superior to mupirocin in the prophylaxis of PD-related infections. Colonization of the exit site with fungal organisms is of concern and warrants further study. As such, the use of P(3) over mupirocin is not advocated in the prophylaxis of PD-related infections.
Figures
Similar articles
-
A randomized controlled trial comparing mupirocin versus Polysporin Triple for the prevention of catheter-related infections in peritoneal dialysis patients (the MP3 study).Perit Dial Int. 2008 Jan-Feb;28(1):67-72. Perit Dial Int. 2008. PMID: 18178950 Clinical Trial.
-
The association between exit site infection and subsequent peritonitis among peritoneal dialysis patients.Clin J Am Soc Nephrol. 2012 Aug;7(8):1266-71. doi: 10.2215/CJN.00980112. Epub 2012 Jun 28. Clin J Am Soc Nephrol. 2012. PMID: 22745277 Free PMC article. Clinical Trial.
-
Prevention of peritoneal dialysis catheter infections in Saudi peritoneal dialysis patients: the emergence of high-level mupirocin resistance.Int J Artif Organs. 2013 Jul;36(7):473-83. doi: 10.5301/ijao.5000207. Epub 2013 May 16. Int J Artif Organs. 2013. PMID: 23897229
-
Epidemiology, management, and prevention of exit site infections in peritoneal dialysis patients.Ther Apher Dial. 2022 Apr;26(2):275-287. doi: 10.1111/1744-9987.13726. Epub 2021 Sep 7. Ther Apher Dial. 2022. PMID: 34435734 Review.
-
Effect of preventing Staphylococcus aureus carriage on rates of peritoneal catheter-related staphylococcal infections. Literature synthesis.Perit Dial Int. 2001 Sep-Oct;21(5):471-9. Perit Dial Int. 2001. PMID: 11757831 Review.
Cited by
-
Comparative Effectiveness of Local Application of Chlorhexidine Gluconate, Mupirocin Ointment, and Normal Saline for the Prevention of Peritoneal Dialysis-related Infections (COSMO-PD Trial): a multicenter randomized, double-blind, controlled protocol.Trials. 2019 Dec 19;20(1):754. doi: 10.1186/s13063-019-3953-8. Trials. 2019. PMID: 31856900 Free PMC article.
-
Blisters and Milia around the Peritoneal Dialysis Catheter: A Case of Localized Bullous Pemphigoid.Dermatopathology (Basel). 2022 Aug 4;9(3):282-286. doi: 10.3390/dermatopathology9030033. Dermatopathology (Basel). 2022. PMID: 35997350 Free PMC article.
-
Central Venous Catheters for Hemodialysis-the Myth and the Evidence.Kidney Int Rep. 2021 Oct 11;6(12):2958-2968. doi: 10.1016/j.ekir.2021.09.009. eCollection 2021 Dec. Kidney Int Rep. 2021. PMID: 34901568 Free PMC article. Review.
-
A contemporary approach to the prevention of peritoneal dialysis-related peritonitis in children: the role of improvement science.Pediatr Nephrol. 2017 Aug;32(8):1331-1341. doi: 10.1007/s00467-016-3531-1. Epub 2016 Oct 18. Pediatr Nephrol. 2017. PMID: 27757588 Review.
-
Peritoneal dialysis associated infections: An update on diagnosis and management.World J Nephrol. 2012 Aug 6;1(4):106-22. doi: 10.5527/wjn.v1.i4.106. World J Nephrol. 2012. PMID: 24175248 Free PMC article. Review.
References
-
- Mujais S: Microbiology and outcomes of peritonitis in North America. Kidney Int Suppl 103: S55–S62, 2006 - PubMed
-
- Johnson DW, Dent H, Hawley CM, McDonald SP, Rosman JB, Brown FG, Bannister KM, Wiggins KJ: Associations of dialysis modality and infectious mortality in incident dialysis patients in Australia and New Zealand. Am J Kidney Dis 53: 290–297, 2009 - PubMed
-
- Li PK, Szeto CC, Piraino B, Bernardini J, Figueiredo AE, Gupta A, Johnson DW, Kuijper EJ, Lye WC, Salzer W, Schaefer F, Struijk DG: Peritoneal dialysis-related infections recommendations: 2010 update. Perit Dial Int 30: 393–423, 2010 - PubMed
-
- Al-Hilali NA, Ninan VT, Al-Humoud HA, Nampoory MR, Johny KV: Mupirocin once weekly reduces the incidence of catheter exit-site infection in peritoneal dialysis patients. Perit Dial Int 25: 91–92, 2005 - PubMed
-
- Aykut S, Caner C, Ozkan G, Ali C, Tugba A, Zeynep G, Taner C: Mupirocin application at the exit site in peritoneal dialysis patients: Five years of experience. Ren Fail 32: 356–361, 2010 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials